UnknownPhase 3NCT00041210
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
- Principal Investigator
- Peter J. Hoskin, MDMount Vernon Cancer Centre at Mount Vernon Hospital
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 850 target
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2001
Study locations (30)
- Basildon University Hospital, Basildon, England, United Kingdom
- Royal United Hospital, Bath, England, United Kingdom
- Kent and Canterbury Hospital, Canterbury, England, United Kingdom
- Saint Richards Hospital, Chichester, England, United Kingdom
- Walsgrave Hospital, Coventry, England, United Kingdom
- Doncaster Royal Infirmary, Doncaster, England, United Kingdom
- Russells Hall Hospital, Dudley, England, United Kingdom
- Royal Devon and Exeter Hospital, Exeter, England, United Kingdom
- Hemel Hempstead General, Hemel Hempstead, England, United Kingdom
- Hull Royal Infirmary, Hull, England, United Kingdom
- King George Hospital, Ilford, Essex, England, United Kingdom
- Lincoln County Hospital, Lincoln, England, United Kingdom
- Royal Liverpool University Hospital, Liverpool, England, United Kingdom
- Aintree University Hospital, Liverpool, England, United Kingdom
- Saint Bartholomew's Hospital, London, England, United Kingdom
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00041210 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →